Latest Innovation News

Cadoux Limited has made significant progress in developing its high purity alumina and rare earths projects, advancing engineering design, customer engagement, and funding strategies during the June 2025 quarter.

Red Metal Limited’s June 2025 Quarterly Report highlights significant metallurgical advances at its Sybella rare earth project and accelerated drilling programs across copper-gold and gold targets, supported by government grants and resource upgrades.

Eden Innovations reports a striking 114% year-on-year jump in Q4 US sales of its EdenCrete® products, alongside a 50% annual sales increase and significant debt reduction plans.

Fintech Chain Limited reported a mixed quarter with strong customer receipts and new IoT SaaS product launch, while finalising its ASX delisting. The company’s cash position tightened amid loan repayments and rising operating costs.

Prescient Therapeutics has raised nearly $10 million through a placement and share purchase plan to advance its promising PTX-100 targeted cancer therapy into pivotal clinical stages.

Greenwing Resources reports solid progress across its lithium and graphite assets in Argentina, Madagascar, and Tasmania, completing a $3.5 million equity raise and appointing a new chairman.

NoviqTech launches Quantum Intelligence Pty Ltd, introducing hybrid quantum computing solutions with a $1.25 million placement to accelerate growth and product rollout.

Hartshead Resources NL reports steady progress on its P2607 gas development in the UK Southern North Sea, supported by a strong cash position and ongoing joint venture negotiations with RockRose Energy.

Meteoric Resources has announced a maiden Ore Reserve at its Caldeira Project alongside a breakthrough processing partnership and a heavily oversubscribed $42.5 million equity raise, positioning it as a key player in the evolving rare earths market.

ClearVue Technologies has announced a major leadership overhaul alongside strategic partnerships and market expansion, highlighted by a solar façade trial in Hong Kong demonstrating a payback period as low as 2.6 years.

Resonance Health reports a solid quarter with key clinical trial milestones, expansion of trial sites, and multi-year Software-as-a-Medical Device contracts, underpinning a positive cashflow outlook.

Starpharma reports a 165% rise in FY25 customer receipts, advances its clinical-stage DEP® assets, and secures new distribution deals in Asia and Saudi Arabia.